Skip to content

Study · In vitro (cells) · 2005

2 results

Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid.

Zatelli MC, Maffei P, Piccin D, Martini C, Rea F, Rubello D, Margutti A, Culler MD, Sicolo N, degli Uberti EC

The Journal of clinical endocrinology and metabolism25 Jan 2005Cited by 30 (Europe PMC)

PMID15671091 (opens in a new tab)DOI10.1210/jc.2004-2156 (opens in a new tab)PepBankPUB-15671091
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In cultured human bronchial carcinoid cells, lanreotide significantly reduced GHRH secretion by 35%.

    In plain wordsIn cells from a human bronchial carcinoid, lanreotide reduced GHRH secretion.

    Peptide
    Lanreotide
    Outcome
    DecreaseGHRH secretion
    Study

    humann: not reported in source

    cultured bronchial atypical carcinoid cells
    Outcome group
    Growth hormone and IGF-1 · Cancer
    Studied dose
    Dose not stated · 6 hAs given in this study (human).

    Source sentences

    Summary
    GHRH secretion was significantly reduced by SRIH (-50%), Lan (-35%), as well as by the SSTR2, SSTR5, and SSTR1 selective agonists (-55, -75, and -20%, respectively), whereas cell viability was not affected.
    2 context sentences
    Summary · context
    Cultured tumor cells were treated with SRIH, lanreotide (BIM-23014), or SRIH analogs selective for SSTR2 (BIM-23120), SSTR5 (BIM-23206), or SSTR1 (BIM-23926).
    Summary · context
    GHRH was measured in the medium after 6 h, and cell viability was assessed after 48 h.
  2. 02LabIn vitro (cells)Activity measurement

    In cultured human bronchial carcinoid cells, lanreotide did not affect cell viability.

    In plain wordsIn cells from a human bronchial carcinoid, lanreotide did not affect cell viability.

    Peptide
    Lanreotide
    Outcome
    No significant changeCell viability
    Study

    humann: not reported in source

    cultured bronchial atypical carcinoid cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 48 hAs given in this study (human).

    Source sentences

    Summary
    GHRH secretion was significantly reduced by SRIH (-50%), Lan (-35%), as well as by the SSTR2, SSTR5, and SSTR1 selective agonists (-55, -75, and -20%, respectively), whereas cell viability was not affected.
    2 context sentences
    Summary · context
    Cultured tumor cells were treated with SRIH, lanreotide (BIM-23014), or SRIH analogs selective for SSTR2 (BIM-23120), SSTR5 (BIM-23206), or SSTR1 (BIM-23926).
    Summary · context
    GHRH was measured in the medium after 6 h, and cell viability was assessed after 48 h.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.